272 related articles for article (PubMed ID: 2567208)
1. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
Tricot GJ; Jayaram HN; Lapis E; Natsumeda Y; Nichols CR; Kneebone P; Heerema N; Weber G; Hoffman R
Cancer Res; 1989 Jul; 49(13):3696-701. PubMed ID: 2567208
[TBL] [Abstract][Full Text] [Related]
2. Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
Tricot G; Weber G
Anticancer Res; 1996; 16(6A):3341-7. PubMed ID: 9042309
[TBL] [Abstract][Full Text] [Related]
3. Enzyme-pattern-targeted chemotherapy with tiazofurin and allopurinol in human leukemia.
Weber G; Jayaram HN; Lapis E; Natsumeda Y; Yamada Y; Yamaji Y; Tricot GJ; Hoffman R
Adv Enzyme Regul; 1988; 27():405-33. PubMed ID: 2907968
[TBL] [Abstract][Full Text] [Related]
4. Tiazofurin: molecular and clinical action.
Weber G; Prajda N; Abonyi M; Look KY; Tricot G
Anticancer Res; 1996; 16(6A):3313-22. PubMed ID: 9042306
[TBL] [Abstract][Full Text] [Related]
5. Tiazofurin: biological effects and clinical uses.
Tricot G; Jayaram HN; Weber G; Hoffman R
Int J Cell Cloning; 1990 May; 8(3):161-70. PubMed ID: 2189014
[TBL] [Abstract][Full Text] [Related]
6. Sequential impact of tiazofurin and ribavirin on the enzymic program of the bone marrow.
Prajda N; Hata Y; Abonyi M; Singhal RL; Weber G
Cancer Res; 1993 Dec; 53(24):5982-6. PubMed ID: 7903199
[TBL] [Abstract][Full Text] [Related]
7. Hematological and biochemical action of tiazofurin (NSC 286193) in a case of refractory acute myeloid leukemia.
Tricot GJ; Jayaram HN; Nichols CR; Pennington K; Lapis E; Weber G; Hoffman R
Cancer Res; 1987 Sep; 47(18):4988-91. PubMed ID: 3476200
[TBL] [Abstract][Full Text] [Related]
8. Tiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis.
Wright DG; Boosalis MS; Waraska K; Oshry LJ; Weintraub LR; Vosburgh E
Anticancer Res; 1996; 16(6A):3349-51. PubMed ID: 9042310
[TBL] [Abstract][Full Text] [Related]
9. Critical issues in chemotherapy with tiazofurin.
Weber G
Adv Enzyme Regul; 1989; 29():75-95. PubMed ID: 2699155
[TBL] [Abstract][Full Text] [Related]
10. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part I. In vivo studies.
Malek K; Boosalis MS; Waraska K; Mitchell BS; Wright DG
Leuk Res; 2004 Nov; 28(11):1125-36. PubMed ID: 15380335
[TBL] [Abstract][Full Text] [Related]
11. Tiazofurin down-regulates expression of c-Ki-ras oncogene in a leukemic patient.
Weber G; Nagai M; Natsumeda Y; Eble JN; Jayaram HN; Paulik E; Zhen WN; Hoffman R; Tricot G
Cancer Commun; 1991 Mar; 3(3):61-6. PubMed ID: 1705812
[TBL] [Abstract][Full Text] [Related]
12. Effects of the inhibitors of IMP dehydrogenase, tiazofurin and mycophenolic acid, on glycoprotein metabolism.
Sokoloski JA; Sartorelli AC
Mol Pharmacol; 1985 Dec; 28(6):567-73. PubMed ID: 2867464
[TBL] [Abstract][Full Text] [Related]
13. Effects of tiazofurin on protooncogene expression during HL-60 cell differentiation.
Kharbanda SM; Sherman ML; Spriggs DR; Kufe DW
Cancer Res; 1988 Nov; 48(21):5965-8. PubMed ID: 2901907
[TBL] [Abstract][Full Text] [Related]
14. Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis.
Jayaram HN; Cooney DA; Grusch M; Krupitza G
Curr Med Chem; 1999 Jul; 6(7):561-74. PubMed ID: 10390601
[TBL] [Abstract][Full Text] [Related]
15. Biochemical consequences of resistance to tiazofurin in human myelogenous leukemic K562 cells.
Jayaram HN; Zhen W; Gharehbaghi K
Cancer Res; 1993 May; 53(10 Suppl):2344-8. PubMed ID: 8097964
[TBL] [Abstract][Full Text] [Related]
16. Alterations in glycoprotein synthesis and guanosine triphosphate levels associated with the differentiation of HL-60 leukemia cells produced by inhibitors of inosine 5'-phosphate dehydrogenase.
Sokoloski JA; Blair OC; Sartorelli AC
Cancer Res; 1986 May; 46(5):2314-9. PubMed ID: 2870796
[TBL] [Abstract][Full Text] [Related]
17. Biochemical differences among four inosinate dehydrogenase inhibitors, mycophenolic acid, ribavirin, tiazofurin, and selenazofurin, studied in mouse lymphoma cell culture.
Lee HJ; Pawlak K; Nguyen BT; Robins RK; Sadée W
Cancer Res; 1985 Nov; 45(11 Pt 1):5512-20. PubMed ID: 2865005
[TBL] [Abstract][Full Text] [Related]
18. IMP dehydrogenase: inhibition by the anti-leukemic drug, tiazofurin.
Yamada Y; Natsumeda Y; Yamaji Y; Jayaram HN; Tricot GJ; Hoffman R; Weber G
Leuk Res; 1989; 13(2):179-84. PubMed ID: 2564451
[TBL] [Abstract][Full Text] [Related]
19. Clinical and molecular impact of inhibition of IMP dehydrogenase activity by tiazofurin.
Weber G; Yamaji Y; Olah E; Natsumeda Y; Jayaram HN; Lapis E; Zhen WN; Prajda N; Hoffman R; Tricot GJ
Adv Enzyme Regul; 1989; 28():335-56. PubMed ID: 2576178
[TBL] [Abstract][Full Text] [Related]
20. IMP dehydrogenase inhibitor, tiazofurin, induces apoptosis in K562 human erythroleukemia cells.
Vitale M; Zamai L; Falcieri E; Zauli G; Gobbi P; Santi S; Cinti C; Weber G
Cytometry; 1997 Feb; 30(1):61-6. PubMed ID: 9056744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
